Valvular & structural heart disease
Lipoprotein(a) Levels in Severe Aortic Stenosis Referred for Transcatheter Aortic Valve Implantation Compared to Controls
Authors' conclusion
Median Lp(a) levels were only mildly higher in severe AS patients undergoing TAVI in comparison to a large control group, mainly driven by higher Lp(a) levels in males. Higher Lp(a) levels were not associated with an earlier age at TAVI, rejecting its association with an accelerated disease progression.
Study context
- Population
- Patients with severe aortic stenosis (AS) referred for transcatheter aortic valve implantation (TAVI), 2012–2017, vs general-population controls
- Participants
- 503 vs 25,343
- Comparison
- Severe AS referred for TAVI vs general-population controls
- TAVIn = 503
- Controlsn = 25,343reference
- Outcome
- Median Lp(a) level
Main finding
As reported in the abstract
Median Lp(a)
P = 0.04
Observational data: associations, not effects.
Further findings
| Outcome | Beta (95% CI) | P value |
|---|---|---|
| Median Lp(a), malesMales with severe AS vs controls: 19.9 vs 16.6 mg/dL | P = 0.04 | |
| Median Lp(a), femalesFemales: 22.1 vs 21.3 mg/dL, nonsignificant difference | P = 0.87 | |
| Lp(a) >50 mg/dL and earlier age at TAVI (multivariable)Not associated with earlier age at TAVI | 1.04 (0.42–2.57) | P = 0.94 |
Original publication
Lipoprotein(a) Levels in Severe Aortic Stenosis Referred for Transcatheter Aortic Valve Implantation Compared to Controls. JACC Adv. Published 5 September 2024. doi:10.
Summarised from the published abstract; every number is checked against it